GenesisCare: $1.7 Billion Cross-Border Chapter 11, 363 Sale and ROW Reorganization

Genesis Care Pty Limited and 52 affiliates filed chapter 11 on June 1, 2023 in the U.S. Bankruptcy Court for the Southern District of Texas, lead case number 23-90614 before Hon. David R. Jones. The Australian-headquartered global oncology operator entered the case with approximately $1.7 billion of funded debt, an $800 million super-priority DIP commitment from its prepetition term lenders, and a dual-track strategy: a Section 363 sale of its U.S. business and a reorganization of the Australian, U.K., and Spanish operations as "Reorganized ROW TopCo."

The filing was driven by a failed integration of 21st Century Oncology, sustained losses in the U.S. business, and a refusal by four of the thirteen RCF banks to fund a draw the company maintained it was entitled to make. Judge Jones confirmed the First Amended Joint Plan on November 22, 2023, and the plan went effective February 16, 2024, cancelling existing TopCo equity, distributing new warrants and cash to senior facility lenders, and leaving U.S. unsecured creditors with no recovery. Reorganized-debtor litigation against multiple sale buyers continued through 2025.

Debtor(s)	Genesis Care Pty Limited (53 jointly administered entities)
Court	U.S. Bankruptcy Court, Southern District of Texas (Houston Division)
Case Number	23-90614
Petition Date	June 1, 2023
Confirmation Date	November 22, 2023
Effective Date	February 16, 2024
Judge	Hon. David R. Jones
DIP Facility	$800 million super-priority term loan from Ad Hoc Term Lender Group ($200M new money / $600M roll-up)
Funded Debt at Filing	Approximately $1.7 billion
Claims Agent	Kroll Restructuring Administration LLC

From KKR Buyout to a Dual-Track Cross-Border Filing

GenesisCare was launched by Dan and Dr. Geoff Holt in partnership with the cardiologists of HeartCare Partners, with DCA Partners as a cornerstone investor. KKR first acquired roughly 45% of the company in 2012, sold its position in 2016 to China Resources Capital — which retained a ~35% stake at filing — and reinvested in October 2018 to take back approximately 30%. Management and physicians held the remaining equity. Alan Carr served as a KKR-designated independent director on the TopCo board through the restructuring.

By the petition date, GenesisCare operated 40 oncology centers in Australia, 14 radiation oncology centers in the U.K., 21 centers in Spain, and 280 U.S. locations across the "GC US" business, and employed more than 5,500 healthcare professionals globally. The company described itself as the world's largest provider of radiotherapy and the largest U.S. employer of urologists. The U.S. footprint was anchored by the May 2020 acquisition of 21st Century Oncology, a network of physician-led cancer treatment centers structured under two operating models: a Company-Owned Business Model with directly employed physicians and a Services Agreement Business Model providing administrative and management services to physician-owned facilities.

The June 1, 2023 filing in Houston was reported the same day as another KKR-backed health care chapter 11, arriving roughly two weeks after Envision Healthcare's filing. Bloomberg coverage flagged the company's plan to sell its U.S. business while reorganizing its international footprint. Industry coverage noted the case was, for some commentators, characterized as a chapter 22 given the company's prior 2020 out-of-court restructuring.

Failed 21C Integration and the Defaulting Banks Liquidity Trigger

The First Day Declaration of CEO David Young identified five overlapping causes of distress, with the first three concentrated on U.S. performance after the 21C acquisition. The 21C integration produced declining revenue cycle management, antiquated IT systems, and aged equipment alongside failed synergies, leaving GC US chronically unprofitable and dependent on cash flow from the Rest of World operations. A second 21C-specific issue compounded the integration failure: because 21C had employed physicians in counties without competing same-specialty practices, non-compete agreements were voided after the acquisition, allowing former 21C-affiliated doctors to open competing centers near GC US locations and recruit the highest-billing physicians, particularly in West Florida.

Beyond the U.S. business, GenesisCare invested in global initiatives that increased overhead without a clear path to positive cash flow. The company concluded by 2023 that it lacked the capital to fund a U.S. turnaround on its own and that a sale of the U.S. business was in the best interest of stakeholders.

The proximate trigger was a lender default. In April 2023, four of the thirteen banks in the company's Revolving Credit Facilities (the "Defaulting Banks") refused to fund draw-down requests for approximately AUD $76 million the company maintained it was entitled to draw. GenesisCare ultimately received only AUD $44 million, accelerating a liquidity crisis that drove the chapter 11 filing weeks later. The Official Committee of Unsecured Creditors subsequently disclosed it was investigating $2.5 million in prepetition retention payments to two top executives made shortly before the filing, alongside the 21C acquisition itself and other prepetition conduct of former directors and officers.

$1.7 Billion Capital Structure and KKR/APH Sponsor Loans

The Debtors entered chapter 11 with approximately $1.7 billion in total funded debt across four prepetition instruments. The senior tranche was a $1,547 million Term Loan B issued in two tranches with maturities in October 2025 and May 2027, secured by first-priority liens on substantially all assets of the guarantors. The TLB carried material exposure in European CLO portfolios, with the default treated as a credit event in the EMEA leveraged credit market. Ranking pari passu with the TLB on shared collateral was an $81 million outstanding balance under the Revolving Credit Facility (RCF1 and RCF2), drawn against an aggregate AUD $200 million commitment. Kroll Agency Services Limited served as facility agent for the Senior Facilities Agreement, and Kroll Trustee Services Limited (formerly Lucid Trustee Services Limited) served as security trustee.

Two sponsor-related loans sat outside the senior facility. The $56 million KKR Loan, originally an AUD $75 million June 2022 emergency loan from a KKR-managed fund to address a prior liquidity shortfall, carried a first lien on substantially all property of TopCo and accrued PIK interest with a maturity extendable to May 30, 2024. A $31 million APH Loan, secured by a second lien on TopCo property and similarly PIK-bearing, had a maturity extendable to January 31, 2024. Both loans were structurally junior to the Senior Facilities Agreement on guarantor collateral but had recourse to TopCo equity value.

The capital structure produced the case's central recovery dynamic: senior facility lenders were undersecured at filing, while the sponsor-related loans relied on equity that the plan ultimately cancelled.

$800 Million DIP Facility and 3:1 Roll-Up Ratio

The Debtors obtained an $800 million super-priority DIP facility from an Ad Hoc Term Lender Group of consenting Senior Facilities Agreement lenders, the "Backstop Parties." The facility carried a 3:1 roll-up to new money ratio: $200 million in new money (a $90 million Initial Term Loan plus $110 million in Delayed Draw Term Loans) against $600 million in roll-ups ($270 million Interim Roll-Up and $330 million Final Roll-Up). The structure converted prepetition senior lender claims to DIP claims at scale and effectively eliminated any meaningful competing DIP alternative.

DIP pricing on the new money tranche was SOFR plus 10.00% per annum (with a 1.00% SOFR floor and customary credit spread adjustments), with 1.50% payable in cash and the remainder PIK. Roll-Up DIP Loans accrued at the non-default rate under the prepetition Senior Facilities Agreement, again with 1.50% cash and the remainder PIK. The Closing Fee was 3.00% of aggregate new money principal (PIK), the Ticking Fee was 0.75% per annum on unfunded new money commitments (PIK), and the Exit Fee was 3.00% of actually funded new money (cash if the Debtors elected repayment).

The DIP matured on the earliest of 364 days after closing, 35 days after Interim Order entry if a Final Order was not entered, consummation of a Section 363 sale of substantially all assets (excluding the U.S. Business), the effective date of a confirmed plan, or acceleration on Event of Default. Adequate protection for prepetition secured parties consisted of Adequate Protection Liens, super-priority claims, and credit-bid rights in any 363 sale up to the full amount of their Adequate Protection Obligations, Prepetition Obligations, and DIP Obligations.

Judge Jones entered the Interim DIP Order on June 2, 2023 and the Final DIP Order on July 19, 2023. Late in the case, the Court approved an additional $20 million in DIP funding over an exit-lender objection that the supplemental financing altered the terms of the confirmed plan and the equity distribution that supported it.

363 Sale of GC US to Multiple Regional Buyers

The case's U.S. track was structured as a Section 363 sale running on tight DIP-driven milestones. Measured from the Petition Date, the DIP imposed sale milestones running from data room access at 10 days through bidding procedures at 45 days, bid deadline at 110 days, auction commencement at 115 days, sale order entry at 125 days, and sale closing at 145 days. The Court entered the Bidding Procedures Order on July 19, 2023, setting a September 22, 2023 bid deadline and an October 4, 2023 auction date. Break-up fees and expense reimbursement were available only to a court-approved Stalking Horse Bidder, and the Debtors were authorized but not obligated to designate one. The auction date and related deadlines were extended at least twice through notices filed October 31 and November 7, 2023.

The sale process did not produce a single going-concern buyer for GC US. The Notice of Winning Bidders filed November 13, 2023 reported that multiple buyers had purchased discrete U.S. practices: Limitless Partners, LLC took three Alabama practices in Andalusia, Enterprise, and Dothan; City Hospital, Inc. doing business as Berkeley Medical Center acquired 60% equity in Ambergris, LLC; American Shared Hospital Services took 60% equity in Southern New England Regional Cancer Center, LLC and Roger Williams Radiation Therapy, LLC, plus certain commercial payor contracts; Greenbelt Radiation Center, LLC purchased one Maryland practice; and Oncology Consultants, PLLC acquired three Nevada practices and a Washington practice. The notice did not disclose an aggregate purchase price for the U.S. sale.

A separate transaction approved under the bidding procedures involved Reorganized Debtor U.S. Cancer Care, Inc. and MRKS, Inc. The parties signed an Investment Agreement on December 7, 2023 for the sale of 100% equity in GenesisCare USA Salinas Valley Memorial Radiation Therapy Management, LLC plus certain acquired contracts. The original purchase price was $3.6 million, subsequently amended to $2.4 million. Memorial Healthcare System — a South Florida hospital network operated by South Broward Hospital District — was among the entities that pursued but did not complete an acquisition of GenesisCare assets, as reflected in its January 2024 board meeting materials. A change-of-control transfer of GenesisCare USA, Inc.'s nuclear byproduct-materials license to Berkeley Medical Center was the subject of a December 21, 2023 NRC consent request, reflecting the regulatory complexity of moving radiation oncology practices between operators.

The sale process drew an objection from Atlantic Urologic Clinics physicians, who argued that prospective bidders were prevented from engaging with physicians about employment terms and that their personal-services employment agreements were not assignable without consent, putting deferred compensation at risk without administrative claim protection. The Debtors and "Doctor Parties" entered multiple stipulations regarding a motion to quash tied to ongoing physician disputes during the case. Bayer Consumer Care AG moved to terminate a clinical trial contract, citing delays caused by the auction process.

Reorganized ROW TopCo and the Class 5B Disparity

The First Amended Joint Chapter 11 Plan, filed November 6, 2023, paired the U.S. 363 sale with a reorganization of the Australian, U.K., and Spanish operations as "Reorganized ROW TopCo." Plan Class 3 — SFA Claims and Swap Claims — was the only impaired voting class. Holders received pro rata shares of New Warrants for 10% of the reorganized equity and Distributable Cash under a waterfall recovery, against undersecured prepetition claims. Class 4 Shareholder Loan Claims (the KKR and APH sponsor loans) were impaired and deemed to reject, receiving no distribution. Class 5A General Unsecured Claims at the ROW Debtors were unimpaired and either reinstated or paid in full. Class 5B General Unsecured Claims at the GC U.S. Debtors were impaired and deemed to reject, with no distribution. Class 8A and 8B existing equity interests in TopCo and U.S. TopCo were impaired and deemed to reject, with no value to holders.

Class	Description	Status	Treatment
Class 1	Other Secured Claims	Unimpaired	Payment in full, reinstatement, or other unimpaired treatment
Class 2	Other Priority Claims	Unimpaired	Payment in full, reinstatement, or other unimpaired treatment
Class 3	SFA Claims and Swap Claims	Impaired (Voting)	Pro rata share of New Warrants and Distributable Cash per Waterfall Recovery
Class 4	Shareholder Loan Claims (KKR / APH)	Impaired (Deemed Reject)	Discharged; no distribution
Class 5A	GUCs (ROW Debtors)	Unimpaired	Reinstated or paid in full
Class 5B	GUCs (GC U.S. Debtors)	Impaired (Deemed Reject)	Discharged; no distribution
Class 6	Intercompany Claims	Per RTM	Per Restructuring Transactions Memorandum
Class 7A/7B	Intercompany Interests	Per RTM	Per Restructuring Transactions Memorandum
Class 8A	Existing TopCo Interests	Impaired (Deemed Reject)	Transferred, cancelled, or combination; no recovery
Class 8B	Existing U.S. TopCo Interests	Impaired (Deemed Reject)	Cancelled (US Equitization) or per RTM (Sale)
Class 9	Section 510(b) Claims	Impaired (Deemed Reject)	Discharged; no distribution

The Official Committee of Unsecured Creditors objected to the disclosure statement on three principal grounds: a premature timeline that left the U.S. sale results and ongoing investigations unresolved at solicitation; disparate creditor treatment, with no recovery for U.S. unsecured creditors (Class 5B) while ROW unsecured creditors (Class 5A) were unimpaired; and overbroad releases under which U.S. unsecured creditors granted broad third-party releases to directors, officers, equity holders, and lenders without reciprocal releases or any distribution. The Committee also raised the equity-flow point that undersecured Class 3 SFA Claim holders received warrants on 10% of reorganized equity while Class 5B received nothing, and disclosed open investigations into the 21C acquisition and prepetition retention payments. The plan was confirmed substantially as filed.

A separate Proskauer Rose-led ad hoc group response from holders of approximately 10% of the DIP loans and 10% of prepetition SFA loans expressed interest in participating in exit capital on a pro rata basis with the Required Lenders, while characterizing the original disclosure statement as "basically a placeholder" given missing Rights Offering documentation and New Money Exit Facility terms. Three individual creditors — Robert Grapin, Valerie & Pieter Mare, and Greg Dunning — filed plan objections, with the Mares filing a competing plan and a separate stay-relief motion that was later withdrawn.

Confirmation was projected to reduce funded debt by $1.5 billion, and the confirmation order was entered November 22, 2023. The plan's debtor releases, third-party releases, exculpation provisions, and supporting injunction were detailed in the Brief in Support of Plan Confirmation. The Plan Effective Date arrived on February 16, 2024, approximately 260 days after the petition date, with confirmation itself reached in roughly 174 days from filing.

Estate Professionals, Critical Vendor Relief, and Patient Care Oversight

The estate professional roster reflected the case's cross-border architecture. Kirkland & Ellis LLP and K&E International served as lead restructuring counsel and requested $11,118,552 in fees plus $108,934 in expenses for the June 1 to August 31, 2023 first interim period. Alvarez & Marsal North America, LLC served as financial advisor at hourly rates of $425 to $1,375 with a $250,000 retainer. PJT Partners LP served as investment banker under a $175,000 monthly advisory fee, an $11 million restructuring fee, or a 1.50% transaction fee. Jackson Walker LLP served as Texas co-counsel, while Herbert Smith Freehills appeared as special foreign counsel for Australia and Clayton UTZ as special investigation counsel. Kobre & Kim LLP, retained as special counsel for Genesis Care Finance Pty Limited, requested $2,482,046 in fees plus $2,237 in expenses for the same first interim period.

The Official Committee of Unsecured Creditors retained Kramer Levin Naftalis & Frankel LLP as co-counsel, which requested $1,434,639 in fees plus $2,344 in expenses for June 20 to August 31, 2023, and Berkeley Research Group, LLC as financial advisor, which requested $2,006,066 in fees plus $817 in expenses for June 22 to August 31, 2023. Locke Lord LLP served as UCC local counsel. The Court entered a general retention order for ordinary course professionals on the operational side, which became the most-referenced order in the case.

The healthcare context shaped the first-day relief. The Court authorized payment of approximately $84.9 million in prepetition critical vendor and patient care claims, authorized continuation of customer programs, and entered procedures for the rejection of executory contracts and unexpired leases. Susan N. Goodman was appointed patient care ombudsman on July 7, 2023, and filed quarterly ombudsman reports throughout the case, providing an independent monitor of patient-care quality during the U.S. wind-down and sale. Australian regulatory implications continued post-emergence: ASIC granted FY23 financial reporting relief to Genesis Care Pty Limited and its subsidiaries on conditions that included disclosure of the chapter 11 proceedings.

MRKS Post-Emergence Dispute and Reorganized Debtor Litigation

The Reorganized Debtors continued to pursue claims against U.S. sale buyers well after the Effective Date. The most active dispute involved MRKS, Inc. The Reorganized Debtors filed a motion to enforce the Investment Agreement on November 5, 2024, seeking approximately $222,603 in unpaid post-closing amounts ($151,482.96 past due plus $71,121.05 in overpayment reimbursement). Judge Jones entered a Show Cause Order on January 22, 2025 regarding MRKS's noncompliance, and the parties held hearings between July 30 and October 29, 2025. The dispute settled on November 19, 2025 under a Stipulation and Agreed Order requiring MRKS to pay $70,000 to the Reorganized Debtors with the remaining $148,558.52 escrow balance returned to MRKS. Earlier in January 2024, a Texas judge had ordered compliance with the chapter 11 plan against a separate shareholder the company alleged was obstructing emergence.

The Reorganized Debtors also pursued the IROC (Interventional Radiation Oncology of California) sale buyer through a closing-related stipulation entered as the transaction wrapped on January 31, 2024. Post-confirmation, the estate filed omnibus claims objections under court-approved procedures entered in 2024, with at least two omnibus objections processed through 2024 and 2025 as the claims register was reconciled.

Fitch's 2024 healthcare bankruptcy enterprise-value case studies cataloged GenesisCare alongside Cano Health among 2024 healthcare emergences, while Fitch's June 2023 default-and-CLO commentary had treated the original filing as a credit event for European CLO portfolios with TLB exposure.

Key Timeline

The following milestones track the case from GenesisCare's June 2023 petitions through plan effectiveness and post-emergence disputes.

Frequently Asked Questions

Who is the claims agent for GenesisCare?

Kroll Restructuring Administration LLC serves as the claims and noticing agent. The firm maintains the official claims register and distributes case notifications to creditors and parties in interest.

What was the size of the GenesisCare DIP facility?

The Court authorized an $800 million super-priority, multiple-draw term loan DIP facility from an Ad Hoc Term Lender Group, structured as $200 million in new money and $600 million in roll-ups of prepetition Senior Facilities Agreement obligations. The Court later approved an additional $20 million in DIP funding over a lender objection.

Did U.S. unsecured creditors recover anything under the plan?

No. Class 5B General Unsecured Claims at the GC U.S. Debtors were impaired and deemed to reject, receiving no distribution. ROW general unsecured claims (Class 5A) were unimpaired. Senior Facilities Agreement and Swap Claim holders (Class 3) received pro rata shares of New Warrants for 10% of reorganized equity and Distributable Cash under the waterfall.

Was the U.S. business sold to a single buyer?

No. The November 13, 2023 Notice of Winning Bidders identified multiple buyers for discrete U.S. practices, including Limitless Partners (Alabama), Berkeley Medical Center (Ambergris equity), American Shared Hospital Services (Southern New England and Roger Williams equity), Greenbelt Radiation Center (Maryland), and Oncology Consultants (Nevada and Washington). MRKS, Inc. separately purchased the Salinas Valley entity for $2.4 million.

For more bankruptcy case coverage, visit the ElevenFlo bankruptcy blog.